# A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia

> **NCT07634198** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Nanjing Yoko Biomedical Co., Ltd.** · enrollment: 590 (estimated)

## Conditions studied

- Hospital-acquired Bacterial Pneumonia (HABP)
- Ventilator-associated Bacterial Pneumonia (VABP)

## Interventions

- **DRUG:** YK-1169
- **DRUG:** Ceftazidime-avibactam Injection

## Key facts

- **NCT ID:** NCT07634198
- **Lead sponsor:** Nanjing Yoko Biomedical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-04
- **Primary completion:** 2028-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 590 (ESTIMATED)
- **Last updated:** 2026-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07634198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07634198, "A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07634198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*